PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsDisopyramide
Disopyramide
Disopyramide, Norpace (disopyramide) is a small molecule pharmaceutical. Disopyramide was first approved as Norpace on 1982-01-01. It is used to treat atrial fibrillation, atrial flutter, cardiac arrhythmias, and ventricular premature complexes in the USA. It is known to target voltage-gated inwardly rectifying potassium channel KCNH2; potassium voltage-gated channel subfamily H member 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Disopyramide, Norpace (discontinued: Disopyramide)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Disopyramide phosphate
Tradename
Company
Number
Date
Products
NORPACEPfizerN-017447 RX1982-01-01
2 products, RLD, RS
NORPACE CRPfizerN-018655 RX1982-07-20
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
disopyramide phosphateANDA2024-03-01
disopyramide phosphate er2007-02-21
norpaceNew Drug Application2010-02-24
norpace norpace crNew Drug Application2024-08-16
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
atrial fibrillationEFO_0000275D001281I48.0
atrial flutterEFO_0003911D001282—
cardiac arrhythmiasEFO_0004269D001145I49.9
ventricular premature complexes—D018879I49.3
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C01: Cardiac therapy drugs
— C01B: Antiarrhythmics, class i and iii
— C01BA: Antiarrhythmics, class ia
— C01BA03: Disopyramide
HCPCS
No data
Clinical
Clinical Trials
7 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atrial fibrillationD001281EFO_0000275I48.0——2—13
Heart failureD006333HP_0001635I50——1——1
Cardiovascular diseasesD002318HP_0001626———1——1
Heart diseasesD006331EFO_0003777I51.9——1——1
Cardiac arrhythmiasD001145EFO_0004269I49.9——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hypertrophic cardiomyopathyD002312EFO_0000538I42.1—2——24
CardiomyopathiesD009202EFO_0000318I42—2——24
HypertrophyD006984EFO_0002460——2——24
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDisopyramide
INNdisopyramide
Description
Disopyramide is a monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug. It has a role as an anti-arrhythmia drug. It is a monocarboxylic acid amide, a member of pyridines and a tertiary amino compound.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C
Identifiers
PDB—
CAS-ID3737-09-5
RxCUI—
ChEMBL IDCHEMBL517
ChEBI ID4657
PubChem CID3114
DrugBankDB00280
UNII IDGFO928U8MQ (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
KCNH2
KCNH2
Organism
Homo sapiens
Gene name
KCNH2
Gene synonyms
ERG, ERG1, HERG
NCBI Gene ID
3757
Protein name
potassium voltage-gated channel subfamily H member 2
Protein synonyms
Eag homolog, Eag-related protein 1, ERG-1, Ether-a-go-go-related gene potassium channel 1, ether-a-go-go-related potassium channel protein, Ether-a-go-go-related protein 1, H-ERG, hERG-1, hERG1, human ether-a-go-go-related, long QT syndrome type 2, potassium channel, voltage gated eag related subfamily H, member 2, potassium voltage-gated channel, subfamily H (eag-related), member 2, Voltage-gated potassium channel subunit Kv11.1
Uniprot ID
Q9H3P0
Mouse ortholog
Kcnh2 (16511)
potassium voltage-gated channel subfamily H member 2 (O35989)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Disopyramide
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 2,623 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
918 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use